Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials

References

• Rawshani A Rawshani A Franzén S Mortality and cardiovascular disease in type 1 and type 2 diabetes N Engl J Med 2017 376 15 1407 1418 28402770
   PubMed Web of Science ®Google Scholar
• Fox CS Golden SH Anderson C Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care 2015 38 9 1777 1803 26246459
   PubMed Web of Science ®Google Scholar
• Piepoli MF Hoes AW Agewall S 2016 European guidelines on cardiovascular disease prevention in clinical practice Rev Esp Cardiol 2016 69 10 939 27692125
   PubMed Web of Science ®Google Scholar
• Rao Kondapally Seshasai S Kaptoge S Thompson A Diabetes mellitus, fasting glucose, and risk of cause-specific death N Engl J Med 2011 364 9 829 841 21366474
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation IDF Diabetes Atlas 8th ed 2017 Available from: http://diabetesatlas.org/resources/2017-atlas.html Accessed February 18, 2019
   Google Scholar
• Vazquez-Benitez G Desai JR Xu S Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis Diabetes Care 2015 38 5 905 912 25710922
   PubMed Web of Science ®Google Scholar
• Khaw KT Wareham N Luben R Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and nutrition (EPIC-Norfolk) BMJ 2001 322 7277 15 18 11141143
   PubMed Web of Science ®Google Scholar
• Stratton IM Adler AI Neil HA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 7258 405 412 10938048
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2015 38 1 140 149 25538310
   PubMed Web of Science ®Google Scholar
• Davies MJ D’Alessio DA Fradkin J Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2018 41 12 2669 2701 30291106
   PubMed Web of Science ®Google Scholar
• Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007 356 24 2457 2471 17517853
   PubMed Web of Science ®Google Scholar
• Food US Administration Drug Guidance for industry: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes 2008 Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Accessed February 18, 2019
   Google Scholar
• Zinman B Wanner C Lachin JM Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 2015 373 22 2117 2128 26378978
   PubMed Web of Science ®Google Scholar
• Neal B Perkovic V Mahaffey KW Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 2017 377 7 644 657 28605608
   PubMed Web of Science ®Google Scholar
• Marso SP Daniels GH Brown-Frandsen K Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 2016 375 4 311 322 27295427
   PubMed Web of Science ®Google Scholar
• American Diabetes Association (ADA) Standards of medical care in diabetes J Clin Appl Res Educ 2017 40 142
   Google Scholar
• UKPDS Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998 352 9131 854 865 9742977
   PubMed Web of Science ®Google Scholar
• Monami M Genovese S Mannucci E Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials Diabetes Obes Metab 2013 15 10 938 953 23594109
   PubMed Web of Science ®Google Scholar
• Home PD Pocock SJ Beck-Nielsen H Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 2009 373 9681 2125 2135 19501900
   PubMed Web of Science ®Google Scholar
• Nissen SE Rosiglitazone: a case of regulatory hubris BMJ 2013 347 f7428 24335808
   PubMed Web of Science ®Google Scholar
• Mendes D Alves C Batel-Marques F Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone Pharmacoepidemiol Drug Saf 2015 24 12 1259 1270 26376779
   PubMed Web of Science ®Google Scholar
• Zou C Hu H Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk Vasc Health Risk Manag 2013 9 429 433 24023518
   PubMedGoogle Scholar
• Azimova K San Juan Z Mukherjee D Cardiovascular safety profile of currently available diabetic drugs Ochsner J 2014 14 4 616 632 25598727
   PubMedGoogle Scholar
• NAVIGATOR Study Group McMurray JJ Holman RR Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 2010 362 16 1477 1490 20228403
   PubMed Web of Science ®Google Scholar
• Holman RR Coleman RL Chan JCN Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol 2017 5 11 877 886 28917545
   PubMed Web of Science ®Google Scholar
• Zhuang XD He X Yang DY Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials Cardiovasc Diabetol 2018 17 1 79 29871636
   PubMed Web of Science ®Google Scholar
• Scirica BM Bhatt DL Braunwald E Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 369 14 1317 1326 23992601
   PubMed Web of Science ®Google Scholar
• White WB Pratley R Fleck P Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus Diabetes Obes Metab 2013 15 7 668 673 23489301
   PubMed Web of Science ®Google Scholar
• Green JB Bethel MA Armstrong PW Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N Engl J Med 2015 373 3 232 242 26052984
   PubMed Web of Science ®Google Scholar
• Fei Y Tsoi MF Kumana CR Cheung TT Cheung BMY Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs Int J Cardiol 2018 254 291 296 29277321
   PubMed Web of Science ®Google Scholar
• Cardiovascular and renal microvascular outcome study with linagliptin in patients with type 2 diabetes mellitus (CARMELINA) Presented at the European Association for the Study of Diabetes (EASD) 2018 annual meeting Berlin, Germany 2018 Available from: https://www.easd.org/virtualmeeting/home.html#!contentsessions/2873 Accessed November 13, 2018
   Google Scholar
• Scirica BM Braunwald E Raz I Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial Circulation 2014 130 18 1579 1588 25189213
   PubMed Web of Science ®Google Scholar
• Zannad F Cannon CP Cushman WC Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in examine: a multicentre, randomised, double-blind trial Lancet 2015 385 9982 2067 2076 25765696
   PubMed Web of Science ®Google Scholar
• Verma S Goldenberg RM Bhatt DL Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis CMAJ Open 2017 5 1 E152 E177
   Google Scholar
• Wu JH Foote C Blomster J Effects of sodium-glucose cotrans-porter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis Lancet Diabetes Endocrinol 2016 4 5 411 419 27009625
   PubMed Web of Science ®Google Scholar
• Lee G Oh SW Hwang SS Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: a network meta-analysis PLoS One 2017 12 5 e0177646 28542373
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmacueticals Inc Jardiance (empagliflozin) prescribing information Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s008lbl.pdf Accessed September 25, 2018
   Google Scholar
• American Diabetes Association 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018 Diabetes Care 2018 41 Supplement 1 S73 S85 29222379
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes Diabetes Care 2017 40 Supplement 1 S1 S131 27979885
   PubMedGoogle Scholar
• Wiviott SD Raz I Bonaca MP Dapagliflozin and cardiovascular outcomes in type 2 diabets N Engl J Med 2019 380 4 347 357 30415602
   PubMed Web of Science ®Google Scholar
• Zhang X Shao F Zhu L Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis BMC Pharmacol Toxicol 2018 19 1 58 30223891
   PubMed Web of Science ®Google Scholar
• Wang Q Liu L Gao L Li Q Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: a meta-analysis of cardiovascular outcomes trials Diabetes Res Clin Pract 2018 143 34 42 29935211
   PubMed Web of Science ®Google Scholar
• Hernandez AF Green JB Janmohamed S Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (HARMONY Outcomes): a double-blind, randomised placebo-controlled trial Lancet 2018 392 10157 1519 1529 30291013
   PubMed Web of Science ®Google Scholar
• Marso SP Bain SC Consoli A Semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 2016 375 19 1834 1844 27633186
   PubMed Web of Science ®Google Scholar
• Novo Nordisk Victoza (liraglutide), prescribing information 2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf Accessed September 25, 2018
   Google Scholar
• Pfeffer MA Claggett B Diaz R Lixisenatide in patients with type 2 diabetes and acute coronary syndrome N Engl J Med 2015 373 23 2247 2257 26630143
   PubMed Web of Science ®Google Scholar
• Holman RR Bethel MA Mentz RJ Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes N Engl J Med 2017 377 13 1228 1239 28910237
   PubMed Web of Science ®Google Scholar
• del Olmo-Garcia MI Merino-Torres JF GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes J Diabetes Res 2018 2018 4020492 29805980
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators Gerstein HC Bosch J Basal insulin and cardiovascular and other outcomes in dysglycemia N Engl J Med 2012 367 4 319 328 22686416
   PubMed Web of Science ®Google Scholar
• Marso SP McGuire DK Zinman B Efficacy and safety of degludec versus glargine in type 2 diabetes N Engl J Med 2017 377 8 723 732 28605603
   PubMed Web of Science ®Google Scholar
• Kosiborod M Cavender MA Fu AZ Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors) Circulation 2017 136 3 249 259 28522450
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Khan R Insulin-associated weight gain in diabetes – causes, effects and coping strategies Diabetes Obes Metab 2007 9 6 799 812 17924864
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals Inc Invokana (canagliflozin) prescribing information Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf Accessed November 09, 2018
   Google Scholar
• White WB Cannon CP Heller SR Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 2013 369 14 1327 1335 23992602
   PubMed Web of Science ®Google Scholar
• Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes [press release, 2016] Available from: https://www.intarcia.com/media/media-archive/press-releases/intarcia-announces-successful-cardiovascular-safety-results-in-p.html Accessed September 25, 2018
   Google Scholar
• Novo Nordisk Oral semaglutide demonstrates a favourable cardiovascular safety profile and a significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial [press release, 2018]. Available from: https://www.novonordisk.com/bin/getPDF.2226789.pdf Accessed December 4, 2018
   Google Scholar
• Eli Lilly & Co Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes [press release, 2018]. Available from: https://investor.lilly.com/node/39796/pdf Accessed November 12, 2018
   Google Scholar